Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 1999

View Archived Issues

Abbott: Q1 1999 highlights

Genelabs and SmithKline Beecham share DARPA grant for drug development

GnRH pharmaccine reduces testosterone to castration levels

AVI confirms that classic approaches valid for testing antisense compound

Efficacy of IL-2 Gene Medicine is enhanced by combination with chemotherapeutic agent

News from FASEB: CT-3 is a potent and long-acting analgesic with good tolerability

Phytopharm reports preliminary phase IIa results for P-54 in osteoarthritis

Novavax estrogen cream completes phase II trial

Oxazolidinones useful for resistant Gram-positive infections

Abarelix depot is safe and effective in patients with endometriosis

Inhibitors of PTKs and T-cell activation/proliferation in development at BMS

Shiseido provides methods of promoting hair regrowth

Aminomethyl benzofuran-based compounds as potent and selective 5-HT1A receptor ligands

Novel cytotoxic agent from Nippon Steel with potential in inflammation and osteoporosis

Taro evaluates anticonvulsant barbiturate compounds in dog model

Merck identifies a nonpeptide, linearly minimized, centrally constrained gpIIb/IIIa antagonist

News from FASEB: novel factor Xa inhibitor presented by DuPont Pharmaceuticals

Fujisawa, Quark collaborate on genomics research in the area of stroke

Amoxil cleared for b.i.d. dosing in children

Immunization strategy effectively blocks the behavioral effects of cocaine in monkeys

TerraGen raises financing, changes name to reflect expanded capabilities

Progen's heparanase inhibitor prevents restenosis in experimental model

Nabi nicotine vaccine shows promise in preclinical studies

Monsanto responds to press publication of Celebrex adverse events

PNU-159548 undergoes phase I trials; preclinical results presented at AACR meeting

TP-508 promotes the wound-healing process via a novel mechanism

Promising phase I/II data for 81C6 pave the way for phase III trials in brain tumor patients

Favorable efficacy and safety profile of CEP-701 in PDAC

Extensive preclinical evaluation establishes potential of novel antitumor agent --CHS-828

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...